Boston Partners
RDHL

Boston Partners’s Redhill Biopharma RDHL Stock Holding History

Boston Partners’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10
Closed -$58K – 725
2019
Q4 		$58K Sell
10
-17
-63% -$109K ﹤0.01% 672
2019
Q3 		$190K Buy
+27
New +$197K ﹤0.01% 642

Other funds holding RDHL

II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners's RDHL Position: Q1 2020 in Review

Boston Partners sold out of Redhill Biopharma (RDHL) in Q1 2020, closing a stake of 10 shares — an estimated $58K sold.

Boston Partners first reported a position in RDHL in Q3 2019 and held it in 2 quarters. The position peaked at $190K in Q3 2019. 46 funds tracked by Wall St. Rank hold RDHL as of Q1 2020.

  • Boston Partners reported no remaining Redhill Biopharma position as of Q1 2020 after selling out during the quarter.
  • Boston Partners sold 10 Redhill Biopharma shares in Q1 2020, an estimated $58K.
  • Boston Partners first reported a position in Redhill Biopharma in Q3 2019 and held it in 2 quarters.
  • Boston Partners's Redhill Biopharma position peaked at $190K in Q3 2019.
  • 46 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2020.

Based on Boston Partners's 13F filing for Q1 2020, filed 13 May 2020.